The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis

Evelyn Balsells¹, Ron Dagan², Inci Yildirim³, Prabhu P Gounder⁴, Anneke Steens⁵, Carmen Muñoz-Almagro⁶, Chiara Mameli⁷, Rama Kandasamy⁸, Noga Givon Lavi², Laura Daprai⁹, Arie van der Ende¹⁰, Krzysztof Trzciński¹¹, Susan A Nzenze¹², Susan Meiring¹³, Dona Foster¹⁴, Lisa R Bulkow⁴, Karen Rudolph⁴, Ana Valero-Rello¹⁵, Struan Ducker¹⁶, Didrik Frimann Vestrheim¹⁷, Anne von Gottberg¹⁸, Stephen I Pelton¹⁹, GianVincenzo Zuccotti⁷, Andrew J Pollard⁸, Elisabeth A M Sanders²⁰, Harry Campbell¹⁶, Shabir A Madhi²¹, Harish Nair²², Moe H Kyaw²³

Affiliations

¹ Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK. Electronic address: e.balsells@ed.ac.uk.
² Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
³ Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Atlanta, GA, USA.
⁴ Arctic Investigations Program, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), US Centers for Disease Control and Prevention (CDC), Anchorage, AK, USA.
⁵ Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
⁶ Institut de Recerca Pediatrica, Departament de Microbiologia Molecular, Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.
⁷ Department of Pediatrics, V.Buzzi Children's Hospital, University of Milan, Milan, Italy.
⁸ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
⁹ Unit of Microbiology, Fondazione IRCCS Cá Granda Ospedale Maggiore Policlinico, Milano, Italy.
¹⁰ Academic Medical Center, Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, The Netherlands.
¹¹ Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
¹² Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.
¹³ National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa.
¹⁴ NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
¹⁵ Institut de Recerca Pediatrica, Departament de Microbiologia Molecular, Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
¹⁶ Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK.
¹⁷ Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway.
¹⁸ National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁹ Department of Pediatrics, Boston Medical Center, Boston, MA, USA.
²⁰ Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands; The National Institute for Public Health and The Environment, Bilthoven, The Netherlands.
²¹ Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.
²² Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK; Public Health Foundation of India, New Delhi, India.
²³ Sanofi Pasteur, Swiftwater, PA, USA.

PMID: 29964140
DOI: 10.1016/j.jinf.2018.06.004

Free article

Meta-Analysis

The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis

Evelyn Balsells et al. J Infect. 2018 Nov.

Free article

. 2018 Nov;77(5):368-378.

doi: 10.1016/j.jinf.2018.06.004. Epub 2018 Jun 30.

Authors

Affiliations

¹ Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK. Electronic address: e.balsells@ed.ac.uk.
² Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
³ Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Atlanta, GA, USA.
⁴ Arctic Investigations Program, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), US Centers for Disease Control and Prevention (CDC), Anchorage, AK, USA.
⁵ Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
⁶ Institut de Recerca Pediatrica, Departament de Microbiologia Molecular, Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.
⁷ Department of Pediatrics, V.Buzzi Children's Hospital, University of Milan, Milan, Italy.
⁸ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
⁹ Unit of Microbiology, Fondazione IRCCS Cá Granda Ospedale Maggiore Policlinico, Milano, Italy.
¹⁰ Academic Medical Center, Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, The Netherlands.
¹¹ Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
¹² Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.
¹³ National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa.
¹⁴ NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
¹⁵ Institut de Recerca Pediatrica, Departament de Microbiologia Molecular, Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
¹⁶ Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK.
¹⁷ Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway.
¹⁸ National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁹ Department of Pediatrics, Boston Medical Center, Boston, MA, USA.
²⁰ Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands; The National Institute for Public Health and The Environment, Bilthoven, The Netherlands.
²¹ Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; National Institute for Communicable Diseases: Division of the National Health Laboratory Service, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.
²² Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, UK; Public Health Foundation of India, New Delhi, India.
²³ Sanofi Pasteur, Swiftwater, PA, USA.

PMID: 29964140
DOI: 10.1016/j.jinf.2018.06.004

Abstract

Objectives: Burden of pneumococcal disease depends on the prevalence and invasive disease potential of serotypes. We aimed to estimate the invasive disease potential of serotypes in children under 5 years of age by combining data from different settings with routine immunisation with pneumococcal conjugate vaccines (PCV).

Methods: We conducted a systematic review, supplemented by unpublished data, to identify data on the frequency of pneumococcal serotypes in carriage and invasive pneumococcal disease (IPD). We estimated the invasive disease potential of serotypes as the ratio of IPD in relation to carriage (odds ratio and 95%CI) compared with 19A (reference serotype) by meta-analysis. We report results based on a random effects model for children aged 0-23, 24-29, and 0-59 months and by invasive clinical syndromes.

Results: In comparison with 19A, serotypes 1, 7F, and 12F had a significantly higher invasive disease potential in children aged 0-23 and 0-59 months for all IPD and clinical syndromes (OR > 5). Several non-vaccine types (NVTs) (6C, 15A, 15BC, 16F, 23B, in these two age groups) had a lower invasive disease potential than 19A (OR 0.1-0.3). NVTs 8, 12F, 24F, and 33F were at the upper end of the invasiveness spectrum.

Conclusions: There is substantial variation among pneumococcal serotypes in their potential to cause IPD and disease presentation, which is influenced by age and time after PCV introduction. Surveillance of IPD and carriage is critical to understand the expected effectiveness of current PCVs (in the longer term) and guide the development of future vaccines.

Keywords: Invasive disease potential; Meta-analysis; Pneumococcal conjugate vaccine; Serotype; Streptococcus pneumoniae.

PubMed Disclaimer

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis

Affiliations

The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical